Co-Authors
This is a "connection" page, showing publications co-authored by Hermann Laferl and Tamara Seitz.
Connection Strength
1.638
-
Successful management of the first reported case in Austria of COVID-19 with ARDS. Infection. 2020 Aug; 48(4):647-651.
Score: 0.887
-
An approach to lifting self-isolation for health care workers with prolonged shedding of SARS-CoV-2 RNA. Infection. 2021 Feb; 49(1):95-101.
Score: 0.227
-
Correction to: COVID-19 is not "just another flu": a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria. Infection. 2021 Oct; 49(5):917.
Score: 0.061
-
High Dose Lopinavir/Ritonavir Does Not Lead to Sufficient Plasma Levels to Inhibit SARS-CoV-2 in Hospitalized Patients With COVID-19. Front Pharmacol. 2021; 12:704767.
Score: 0.060
-
Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention. A comparative cohort study. Infect Dis (Lond). 2021 11; 53(11):820-829.
Score: 0.059
-
COVID-19-associated myoclonus in a series of five critically ill patients. Wien Klin Wochenschr. 2021 Sep; 133(17-18):902-908.
Score: 0.059
-
COVID-19 is not "just another flu": a real-life comparison of severe COVID-19 and influenza in hospitalized patients in Vienna, Austria. Infection. 2021 Oct; 49(5):907-916.
Score: 0.059
-
Clinical and Angiographic Features in Three COVID-19 Patients with Takotsubo Cardiomyopathy. Case Report. SN Compr Clin Med. 2021; 3(1):263-268.
Score: 0.058
-
Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020 11; 8(11):1154-1158.
Score: 0.057
-
Diagnosis of COVID-19 using multiple antibody assays in two cases with negative PCR results from nasopharyngeal swabs. Infection. 2021 Feb; 49(1):171-175.
Score: 0.056
-
Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a real-life patient cohort. Wien Klin Wochenschr. 2021 Apr; 133(7-8):284-291.
Score: 0.056